Pfizer said it expects $32 billion in revenue from Covid-19 vaccines in 2022 as it reported annual profits had more than doubled to $22bn.

The pharmaceutical giant, which with German company BioNTech won approval for the first vaccine to counter the deadly virus, saw annual revenues nearly double to $81.3 billion, with $36.8 billion from the Covid-19 vaccine.

Pfizer also expects $22 billion in sales of Paxlovid, the company's pill for Covid-19, in 2022, AFP reports.